ZIMLAB Stock Overview
Engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ZIM Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹109.95 |
| 52 Week High | ₹131.40 |
| 52 Week Low | ₹89.50 |
| Beta | 0.57 |
| 11 Month Change | 7.47% |
| 3 Month Change | -2.31% |
| 1 Year Change | -4.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.95% |
Recent News & Updates
Recent updates
ZIM Laboratories (NSE:ZIMLAB) Has A Somewhat Strained Balance Sheet
Nov 14
ZIM Laboratories' (NSE:ZIMLAB) Anemic Earnings Might Be Worse Than You Think
May 21Earnings Not Telling The Story For ZIM Laboratories Limited (NSE:ZIMLAB) After Shares Rise 28%
Apr 26ZIM Laboratories Limited's (NSE:ZIMLAB) Shares May Have Run Too Fast Too Soon
Feb 20Estimating The Fair Value Of ZIM Laboratories Limited (NSE:ZIMLAB)
May 16Sentiment Still Eluding ZIM Laboratories Limited (NSE:ZIMLAB)
Nov 29Shareholder Returns
| ZIMLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.5% | 2.3% | 2.4% |
| 1Y | -4.9% | 43.8% | 29.5% |
Return vs Industry: ZIMLAB underperformed the Indian Pharmaceuticals industry which returned 43.8% over the past year.
Return vs Market: ZIMLAB underperformed the Indian Market which returned 29.5% over the past year.
Price Volatility
| ZIMLAB volatility | |
|---|---|
| ZIMLAB Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ZIMLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ZIMLAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 556 | Chandrashekhar Mainde | www.zimlab.in |
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements.
ZIM Laboratories Limited Fundamentals Summary
| ZIMLAB fundamental statistics | |
|---|---|
| Market cap | ₹5.17b |
| Earnings (TTM) | ₹161.50m |
| Revenue (TTM) | ₹3.88b |
33.3x
P/E Ratio1.4x
P/S RatioIs ZIMLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZIMLAB income statement (TTM) | |
|---|---|
| Revenue | ₹3.88b |
| Cost of Revenue | ₹1.89b |
| Gross Profit | ₹1.99b |
| Other Expenses | ₹1.83b |
| Earnings | ₹161.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.31 |
| Gross Margin | 51.36% |
| Net Profit Margin | 4.16% |
| Debt/Equity Ratio | 40.1% |
How did ZIMLAB perform over the long term?
See historical performance and comparison